CTNNA2
CTNNA2 (Catenin alpha-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Hepatocellular carcinoma, Head and neck squamous cell carcinoma and 4 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
May function as a linker between cadherin adhesion receptors and the cytoskeleton to regulate cell-cell adhesion and differentiation in the nervous system. Required for proper regulation of cortical neuronal migration and neurite growth. It acts as a negative regulator of Arp2/3 complex activity and Arp2/3-mediated actin polymerisation. It thereby suppresses excessive actin branching which would impair neurite growth and stability. Regulates morphological plasticity of synapses and cerebellar and hippocampal lamination during development. Functions in the control of startle modulation. Location: Cell membrane; Cytoplasm; Cytoplasm, cytoskeleton; Cell junction, adherens junction (UniProt). Locus 2p12 (HGNC).
- Prostate cancer: IntOGen driver in 4 cohorts (PRAD)
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)
- Biliary tract cancer: IntOGen driver in 2 cohorts (CHOL)
- Non-small-cell lung cancer: IntOGen driver in 2 cohorts (LUAD)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"CTNNA2" OR ABSTRACT:"CTNNA2" OR TITLE:"catenin alpha 2" OR ABSTRACT:"catenin alpha 2" OR TITLE:"Catenin alpha-2" OR ABSTRACT:"Catenin alpha-2" OR TITLE:"CAP-R" OR ABSTRACT:"CAP-R" OR TITLE:"CT114" OR ABSTRACT:"CT114") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CTNNA2, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ctnna2.json. Licence CC BY-NC 4.0.